Literature DB >> 10778867

Elevation of plasma fatty acids by ten-hour intralipid infusion has no effect on basal or glucose-stimulated insulin secretion in normal man.

C M Amery1, R A Round, J M Smith, M Nattrass.   

Abstract

There is controversy over the effect of free fatty acids (FFAs) on insulin secretion. Previous studies have shown opposite effects of short- and long-term exposure to elevated concentrations of FFAs. We studied 8 normal subjects (mean age, 30 years; mean body mass index, 23.4 kg/m2) on 2 occasions. Each had a 10-hour overnight infusion of Intralipid 20% (Pharmacia, Milton Keynes, UK) with simultaneous infusion of heparin (0.4 U/kg body weight/min) or a control infusion of saline (150 mmol/L). Insulin secretion was assessed immediately after completion of the 10-hour infusion by an intravenous glucose tolerance test. Results were analyzed using paired ttests. Intralipid infusion caused an increase in plasma FFAs of more than 9-fold (P < .01), with a simultaneous increase in glycerol (P < .01) and hydroxybutyrate (P < .01). There was no difference in blood glucose concentrations during the infusion or intravenous glucose tolerance test. Similarly, insulin secretion was not significantly different during Intralipid infusion or in the intravenous glucose tolerance test (peak insulin achieved in glucose tolerance test, P = .51; total insulin secretion during intravenous glucose tolerance test, P = .27). In conclusion, after increasing plasma FFA concentrations over 9-fold during a 10-hour infusion of Intralipid and heparin, we found no difference in basal or glucose-stimulated insulin secretion.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10778867     DOI: 10.1016/s0026-0495(00)80007-4

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  7 in total

1.  Effects of acute NEFA manipulation on incretin-induced insulin secretion in participants with and without type 2 diabetes.

Authors:  Brenno Astiarraga; Valéria B Chueire; Aglécio L Souza; Ricardo Pereira-Moreira; Sarah Monte Alegre; Andrea Natali; Andrea Tura; Andrea Mari; Ele Ferrannini; Elza Muscelli
Journal:  Diabetologia       Date:  2018-05-07       Impact factor: 10.122

2.  Vascular effects of intravenous intralipid and dextrose infusions in obese subjects.

Authors:  Aidar R Gosmanov; Dawn D Smiley; Limin Peng; Joselita Siquiera; Gonzalo Robalino; Christopher Newton; Guillermo E Umpierrez
Journal:  Metabolism       Date:  2012-04-05       Impact factor: 8.694

Review 3.  Linoleic acid and the regulation of glucose homeostasis: A review of the evidence.

Authors:  Jakob S Hamilton; Eric L Klett
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2021-10-29       Impact factor: 4.006

4.  β-Cell lipotoxicity after an overnight intravenous lipid challenge and free fatty acid elevation in African American versus American white overweight/obese adolescents.

Authors:  Kara S Hughan; Riccardo C Bonadonna; SoJung Lee; Sara F Michaliszyn; Silva A Arslanian
Journal:  J Clin Endocrinol Metab       Date:  2013-03-22       Impact factor: 5.958

Review 5.  Lessons learned from studying families genetically predisposed to type 2 diabetes mellitus.

Authors:  Kenneth Cusi
Journal:  Curr Diab Rep       Date:  2009-06       Impact factor: 4.810

6.  Intravenous Lipid Infusion Induces Endoplasmic Reticulum Stress in Endothelial Cells and Blood Mononuclear Cells of Healthy Adults.

Authors:  Emmanouil Tampakakis; Corey E Tabit; Monika Holbrook; Erika A Linder; Brittany D Berk; Alissa A Frame; Rosa Bretón-Romero; Jessica L Fetterman; Noyan Gokce; Joseph A Vita; Naomi M Hamburg
Journal:  J Am Heart Assoc       Date:  2016-01-11       Impact factor: 5.501

7.  Impacts of Intralipid on Nanodrug Abraxane Therapy and on the Innate Immune System.

Authors:  Yen-Ju Chen; Chin-Yi Tsai; Ying-Min Cheng; Su-Wen Nieh; Teng-Kuang Yeh; Ching- Ping Chen; Min-Hsien Wang; Ling-Hui Chou; Tai-Yu Chiu; Li Liu; Chien Ho; Chiung- Tong Chen; Tsang-Wu Liu
Journal:  Sci Rep       Date:  2020-02-18       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.